...
首页> 外文期刊>Psychiatry Investigation >Three Cases of Reversible Agranulocytosis after Treatment with Lamotrigine
【24h】

Three Cases of Reversible Agranulocytosis after Treatment with Lamotrigine

机译:拉莫三嗪治疗后可逆性粒细胞缺乏症3例

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Several psychotropic drugs, including clozapine, are known to cause agranulocytosis and this may lead to a fatal condition. Lamotrigine is an anticonvulsant that the Food and Drug Administration (FDA) has approved for the depression of bipolar disorder. A few cases of lamotrigine-induced agranulocytosis have been previously reported on, but the pathophysiology and clinical manifestations are not yet known. This case series reports on 3 patients with different medical conditions who experienced agranulocytosis during treatment with lamotrigine. In these cases, the agranulocytosis occurred a few weeks after initiation of lamotrigine and it rapidly disappeared after discontinuation. We also discuss several characteristics of lamotrigine-induced agranulocytosis.
机译:已知几种精神药物,包括氯氮平,会引起粒细胞缺乏症,并可能导致致命的疾病。拉莫三嗪是食品和药物管理局(FDA)批准的用于治疗躁郁症的抗惊厥药。先前已经报道了几例拉莫三嗪诱导的粒细胞缺乏症,但尚不清楚其病理生理学和临床表现。该病例系列报告了3名不同病情的患者在使用拉莫三嗪治疗期间经历粒细胞缺乏症。在这些情况下,粒细胞缺乏症发生在拉莫三嗪启动后的几周内,停药后迅速消失。我们还讨论了拉莫三嗪诱导的粒细胞缺乏症的几个特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号